<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02751385</url>
  </required_header>
  <id_info>
    <org_study_id>1199.238</org_study_id>
    <secondary_id>2015-005664-41</secondary_id>
    <nct_id>NCT02751385</nct_id>
  </id_info>
  <brief_title>Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Investigate the effect of multiple oral doses of nintedanib on the single dose kinetics of a
      combination of ethinylestradiol and levonorgestrel (Microgynon®)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated- Study halted due to low recruitment.
  </why_stopped>
  <start_date type="Actual">May 20, 2016</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-tz (area under the concentration-time curve of ethinylestradiol before nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-tz (area under the concentration-time curve of levonorgestrel before nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-tz (area under the concentration-time curve of ethinylestradiol after continuous nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC 0-tz (area under the concentration-time curve of levonorgestrel after continuous nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration) of ethinylestradiol before nintedanib administration in plasma</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration) of levonorgestrel before nintedanib administration in plasma</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration) of ethinylestradiol after continuous nintedanib administration in plasma</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration) of levonorgestrel after continuous nintedanib administration in plasma</measure>
    <time_frame>at week 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of ethinylestradiol before nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of levonorgestrel before nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of ethinylestradiol after continuous nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of levonorgestrel after continuous nintedanib administration in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>at week 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Microgynon alone in Period 1 then with Nintedanib in Period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microgynon</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female patients 18 years or older at screening

          -  Female patient is postmenopausal or surgically sterilised

          -  Patient with locally advanced, metastatic or locally recurrent non-small cell lung
             cancer with histology of adenocarcinoma

          -  Nintedanib (Vargatef®) is planned to be prescribed in accordance with the marketing
             authorisation (SmPC)

          -  Signed and dated written informed consent in accordance with Good Clinical Practice
             (GCP) and local legislation prior to admission to the trial

        Exclusion criteria:

          -  Any contraindication to nintedanib (Vargatef®), ethinylestradiol or levonorgestrel
             (Microgynon®), as specified in the respective labels

          -  Use of hormone containing contraceptives (including vaginal and intrauterine devices
             and including hormone replacement therapy) within 30 days prior to first
             administration of Microgynon®

          -  Systemic use of drugs known to induce (e.g. rifampicin, St. John's Wort,
             carbamazepine) or to inhibit (e.g. azole antimycotics, macrolides) CYP3A4 within 7
             days prior to first trial drug administration until last PK-sampling in the trial.
             Exception: allowed is the intake of corticosteroids as docetaxel (pre)medication

          -  History of major thrombotic or clinically relevant major bleeding event in the past 6
             months

          -  Persistence of clinically relevant therapy related toxicities (i.e. &gt; Common
             Terminology Criteria for Adverse Events [CTCAE] grade 2) from previous chemotherapy
             and/or radiotherapy

          -  Treatment with other investigational drugs or treatment in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial

          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of
             the trial drugs

          -  Major surgery (major according to the investigator's assessment) performed within 4
             weeks prior to first treatment within the trial and without complete wound healing

          -  Patients who must or wish to continue the intake of restricted medications or any drug
             considered likely to interfere with the safe conduct of the trial

          -  Patients unable to comply with the protocol

          -  Previous enrolment in this trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

